{"id":1620,"date":"2023-01-20T08:00:00","date_gmt":"2023-01-20T07:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/"},"modified":"2023-05-23T14:11:18","modified_gmt":"2023-05-23T14:11:18","slug":"ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","title":{"rendered":"Ipsen presents Phase III NAPOLI 3 trial of Onivyde\u00ae regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI"},"content":{"rendered":"<p><strong>PARIS, FRANCE,<\/strong>\u00a0January 20, 2023, Ipsen (Euronext: IPN; ADR: IPSEY) today presented positive results from the pivotal Phase III NAPOLI 3 trial evaluating an investigational regimen of Onivyde<sup>\u00ae<\/sup>\u00a0(irinotecan liposome injection), a long-circulating, liposomal topoisomerase inhibitor, in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In a late-breaking abstracts session presentation (LBA661) at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, the data demonstrating investigational novel NALIRIFOX regimen (liposomal irinotecan 50 mg\/m<sup>2<\/sup>\u00a0+ 5-FU 2400 mg\/m<sup>2<\/sup>\u00a0+ leucovorin 400 mg\/m<sup>2<\/sup>\u00a0+ oxaliplatin 60 mg\/m<sup>2<\/sup>) improved overall survival (OS) and progression-free survival (PFS) compared to nab-paclitaxel plus gemcitabine.<sup>1<\/sup>\u00a0At the median follow-up of 16.1 months, the investigational Onivyde regimen met its primary endpoint demonstrating a statistically significant improvement in OS of 11.1 months compared to 9.2 months for patients treated with nab-paclitaxel and gemcitabine (HR 0.83 [95% CI 0.70\u20130.99]; p=0.04).<sup>1\u2020<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-1620","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen presents Phase III NAPOLI 3 trial of Onivyde\u00ae regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI - Annual Report<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen presents Phase III NAPOLI 3 trial of Onivyde\u00ae regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI - Annual Report\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\" \/>\n<meta property=\"og:site_name\" content=\"Annual Report\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-23T14:11:18+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\",\"name\":\"Ipsen presents Phase III NAPOLI 3 trial of Onivyde\u00ae regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI - Annual Report\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\"},\"datePublished\":\"2023-01-20T07:00:00+00:00\",\"dateModified\":\"2023-05-23T14:11:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/annualreport\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen presents Phase III NAPOLI 3 trial of Onivyde\u00ae regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"name\":\"Annual Report\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\",\"name\":\"Annual Report\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"Annual Report\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen presents Phase III NAPOLI 3 trial of Onivyde\u00ae regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI - Annual Report","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","og_locale":"en_US","og_type":"article","og_title":"Ipsen presents Phase III NAPOLI 3 trial of Onivyde\u00ae regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI - Annual Report","og_url":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","og_site_name":"Annual Report","article_modified_time":"2023-05-23T14:11:18+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","url":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/","name":"Ipsen presents Phase III NAPOLI 3 trial of Onivyde\u00ae regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI - Annual Report","isPartOf":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#website"},"datePublished":"2023-01-20T07:00:00+00:00","dateModified":"2023-05-23T14:11:18+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/annualreport\/press-releases\/ipsen-presents-phase-iii-napoli-3-trial-of-onivyde-regimen-demonstrating-positive-survival-results-in-previously-untreated-metastatic-pancreatic-ductal-adenocarcinoma-at-asco-gi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/annualreport\/"},{"@type":"ListItem","position":2,"name":"Ipsen presents Phase III NAPOLI 3 trial of Onivyde\u00ae regimen demonstrating positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma at ASCO GI"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/annualreport\/#website","url":"https:\/\/www.ipsen.com\/annualreport\/","name":"Annual Report","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/annualreport\/#organization","name":"Annual Report","url":"https:\/\/www.ipsen.com\/annualreport\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg","caption":"Annual Report"},"image":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/press_release\/1620"}],"collection":[{"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/press_release\/1620\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/media?parent=1620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/categories?post=1620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/wp-json\/wp\/v2\/tags?post=1620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}